Compare Gilead Sciences, Inc. (GILD) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Moody's Corporation — how do they compare? Gilead Sciences, Inc. trades at $150.84 (market cap $182.40B), while Moody's Corporation trades at $463.69 (market cap $79.44B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× Moody's Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Moody's Corporation for 132 Days on average.
| GILD | MCO | |
|---|---|---|
Market Cap | $182.40B | $79.44B |
Volume | 4,469,821 | 526,684 |
Sector | Health | Financials |
52-Week High | $155.80 | $539.61 |
52-Week Low | $116.74 | $412.23 |
Typical Hold Time | 111 Days | 132 Days |
Enterprise Value | $205.46B | $85.46B |
Dividend Yield | 2.23% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Moody's Corporation (MCO) trades at $462.10, up 2.77% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals with 34.25% net margins and 80.15% ROE, though technical indicators signal near-term bearish pressure. Recent strategic moves include expanding Asia-Pacific presence through a PhilRatings stake and new credit risk product launches.
Outlook remains positive given consistent earnings beats and analyst consensus target of $536.40 (16% upside). Key risks include high valuation multiples (P/E 29.1) and potential macroeconomic sensitivity affecting credit rating demand. Institutional sentiment leans bullish with 56% buy ratings supporting long-term growth thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
